Can We Compare the Four Main Studies of Secondary Prevention of Ischemic Lesions of the Nervous System (European Stroke Prevention Study, United Kingdom-TIA Study, Canadian-American Ticlopidine Study and Swedish Aspirin Low-Dose Trial)?

2015 ◽  
pp. 82-90
Author(s):  
A. Lowenthal ◽  
P. Smets
Keyword(s):  
Nervous System ◽  
United Kingdom ◽  
Secondary Prevention ◽  
Stroke Prevention ◽  
Low Dose ◽  
Prevention Study ◽  
Dose Trial

European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1996 ◽  
Vol 143 (1-2) ◽  
pp. 1-13 ◽  
Author(s):  
H.C. Diener ◽  
L. Cunha ◽  
C. Forbes ◽  
J. Sivenius ◽  
P. Smets ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Acetylsalicylic Acid ◽  
Stroke Prevention ◽  
Prevention Study

scholarly journals Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Andrea DeCensi ◽  
Harriet Johansson ◽  
Thomas Helland ◽  
Matteo Puntoni ◽  
Debora Macis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Low Dose ◽  
Cancer Recurrence ◽  
Phase Iii ◽  
Cyp2d6 Genotype ◽  
Phase Iii Trial ◽  
Reactive Protein ◽  
Non Invasive ◽  
Tamoxifen Metabolites ◽  
Dose Trial

AbstractLow-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 nM) and recurrence, but no association with CYP2D6 was shown in the NSABP P1 and P2 prevention trials. We studied the association of CYP2D6 genotype and tamoxifen metabolites with tumor biomarkers and recurrence in a randomized phase III trial of low-dose tamoxifen. Median (IQR) endoxifen levels at year 1 were 8.4 (5.3–11.4) in patients who recurred vs 7.5 (5.1–10.2) in those who did not recur (p = 0.60). Tamoxifen and metabolites significantly decreased C-reactive protein (CRP, p < 0.05), and a CRP increase after 3 years was associated with higher risk of recurrence (HR = 4.37, 95% CI, 1.14–16.73, P = 0.03). In conclusion, endoxifen is below 9 nM in most subjects treated with 5 mg/day despite strong efficacy and there is no association with recurrence, suggesting that the reason for tamoxifen failure is not poor drug metabolism. Trial registration: ClinicalTrials.gov, Identifier: NCT01357772.

Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients

Dermatology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Efrat Solomon-Cohen ◽  
Shiran Reiss-Huss ◽  
Emmilia Hodak ◽  
Batya Davidovici
Keyword(s):  
Secondary Prevention ◽  
Cell Carcinoma ◽  
Low Dose ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Pretreatment Period ◽  
Solid Organ Transplant Recipients

<b><i>Background:</i></b> Keratinocyte carcinomas, particularly squamous cell carcinoma (SCC), occur more frequently and aggressively in solid-organ transplant recipients (SOTRs) than in the general population. Systemic retinoids are effective in secondary prevention of keratinocyte carcinomas in this population, but their use is limited by adverse effects including a rebound effect in cases of treatment discontinuation. <b><i>Objective:</i></b> Our aim was to determine whether low-dose acitretin is efficient in the secondary prevention of keratinocyte carcinomas in SOTRs. <b><i>Methods:</i></b> This retrospective case-crossover study was conducted at a specialized dermatology clinic for SOTRs in a large transplantation center in 2010–2017. Patients with at least 1 previous keratinocyte carcinoma who were treated with acitretin 10 mg/day for 2 years were included. The main outcome was the difference in the number of new keratinocyte carcinomas diagnosed during treatment compared to during the 2-year pretreatment period. <b><i>Results:</i></b> The cohort included 34 SOTRs. A significant reduction in the mean number of new keratinocyte carcinomas during treatment relative to the pretreatment period was observed (1.7 vs. 3.6, –53% <i>p</i> = 0.002). Similar results were noted on analysis by tumor type, for both SCC and basal cell carcinoma. <b><i>Conclusion:</i></b> This study of SOTRs demonstrated positive results for low-dose acitretin as a chemoprevention of keratinocyte carcinomas in this population.

PCV42 Antiplatelet Treatment Patterns for Secondary Stroke Prevention in the United Kingdom

2021 ◽  
Vol 24 ◽  
pp. S74
Author(s):  
J. Jiang ◽  
D. Li ◽  
J. Horrow ◽  
H. Tamada ◽  
A. Kahl ◽  
...  
Keyword(s):  
United Kingdom ◽  
Stroke Prevention ◽  
Treatment Patterns ◽  
Secondary Stroke Prevention ◽  
Antiplatelet Treatment ◽  
The United Kingdom
Sign in / Sign up

Export Citation Format

Share Document